NuCana plc (NCNA)
Market Cap | 32.49M |
Revenue (ttm) | n/a |
Net Income (ttm) | -41.78M |
Shares Out | 52.40M |
EPS (ttm) | -0.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,960 |
Open | 0.620 |
Previous Close | 0.620 |
Day's Range | 0.602 - 0.640 |
52-Week Range | 0.590 - 1.750 |
Beta | 1.16 |
Analysts | Strong Buy |
Price Target | 4.33 (+598.39%) |
Earnings Date | Nov 15, 2023 |
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluo... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for NCNA stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 598.39% from the latest price.
News

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Ca...

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
On Track to Present Data Updates from All Ongoing Clinical Studies in the Second Half of 2023

NuCana to Present at the Jefferies Healthcare Conference
EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present...

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
Multiple Important Data Readouts Remain on Track for 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ...

NuCana Announces Receipt of Nasdaq Notice
EDINBURGH, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nas...

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer Ac...

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Multiple Important Data Readouts Expected in 2023

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid
Ruling Has No Impact on NuCana's Anti-Cancer ProTide Patents Ruling Has No Impact on NuCana's Anti-Cancer ProTide Patents

NuCana to Participate in Two Upcoming Investor Conferences
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will partici...

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
EDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) f...

NuCana Announces Receipt of NASDAQ Notice
EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Na...

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update
Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022
EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held Septemb...

NuCana to Participate in Citi's 17th Annual BioPharma Conference
EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference.

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update
Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023

Why NuCana Shares Are Rising Today?
Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in Europe...

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent
EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the “Court”)...

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress
NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update
Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer

NuCana to Participate in the 2022 Jefferies Healthcare Conference
EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Jefferies Healthcar...

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update
Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022

NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis